Carbachol/brimonidine ophthalmic solution (Yuvezzi) launches in the US for presbyopia treatment

A fixed-dose combination of carbachol and brimonidine tartrate ophthalmic solution (Yuvezzi; Tenpoint Therapeutics) is now available in the US for the treatment of presbyopia in adults, following FDA approval. The once-daily topical therapy represents a pharmacologic option aimed at improving near visual acuity through a pupil-modulating mechanism, adding to an emerging class of presbyopia-correcting eye drops.

Presbyopia remains a near-universal, age-related condition characterized by progressive loss of accommodation, typically manifesting after age 40 to 45 years. It affects an estimated 128 million individuals in the US and approximately 2 billion globally, with functional consequences that include difficulty reading and performing near tasks under varying lighting conditions.¹⁻³ Until recently, management has relied largely on optical correction (eg, reading glasses, multifocal lenses) or surgical approaches, underscoring ongoing interest in pharmacologic alternatives.

Regulatory and clinical overview

The FDA approval of carbachol/brimonidine ophthalmic solution was based on data from phase 3 clinical trials evaluating the efficacy and safety of the combination in improving near vision in presbyopic adults. Publicly available details on the pivotal trials remain limited at the time of writing. According to the sponsor, the therapy demonstrated improvement in near visual acuity with a duration of effect consistent with once-daily dosing.

The formulation combines 2 pharmacologic agents: carbachol, a direct-acting cholinergic agonist, and brimonidine tartrate, an alpha-2 adrenergic receptor agonist. The proposed mechanism involves induction of miosis to create a “pinhole effect,” increasing depth of focus and thereby improving near vision.⁴ Carbachol stimulates contraction of the iris sphincter and ciliary muscle, while brimonidine inhibits the iris dilator muscle, potentially enhancing and prolonging the miotic response.

Although detailed safety data have not been fully disclosed in the press release, prior experience with miotic agents and alpha-2 agonists suggests potential adverse effects, including headache, dim vision under low-light conditions, conjunctival hyperemia, and, less commonly, systemic adrenergic effects.⁵,⁶ Careful patient selection and counseling may be required, particularly in individuals with preexisting ocular or systemic comorbidities.

Clinical context and treatment landscape

The approval and availability of this dual-agent therapy expand a nascent category of pharmacologic treatments for presbyopia. The first FDA-approved presbyopia eye drop, pilocarpine 1.25% (Vuity; Allergan/AbbVie), demonstrated that miotic therapy could transiently improve near vision without corrective lenses.⁵ However, limitations—including duration of effect, tolerability, and variability in response—have prompted continued development of alternative agents and combinations.

Compared with pilocarpine monotherapy, the addition of brimonidine in the current formulation may offer theoretical advantages in modulating pupil size more selectively and potentially prolonging the duration of action. However, comparative clinical data remain limited, and it is not yet clear whether these pharmacodynamic differences translate into meaningful improvements in efficacy or tolerability.

From a practical standpoint, pharmacologic presbyopia therapies may be most suitable for patients seeking spectacle independence for intermittent near tasks, rather than continuous correction. Clinicians should also consider factors such as baseline pupil size, lighting conditions, occupational needs, and tolerance for potential side effects when discussing treatment options.

Drug background and development

Carbachol has long been used in ophthalmology for intraoperative miosis and glaucoma management, while brimonidine is widely prescribed for lowering intraocular pressure in patients with glaucoma or ocular hypertension.⁶,⁷ The combination of these agents for presbyopia reflects a repurposing strategy aimed at leveraging complementary mechanisms of action.

The development of combination miotic therapies aligns with broader efforts to optimize pharmacologic presbyopia correction by balancing efficacy, duration, and tolerability. Several investigational agents—including other cholinergic combinations and lens-softening therapies—remain under study.⁸

Interpretation and remaining questions

Although the availability of carbachol/brimonidine ophthalmic solution provides an additional option for the management of presbyopia, its place in therapy will depend on real-world effectiveness, patient adherence, and tolerability.

Key unanswered questions include the consistency of response across age groups and refractive profiles, long-term safety with chronic use, and comparative performance against existing therapies. Postmarketing surveillance and future peer-reviewed publications, along with longer-term clinical experience, will be important in clarifying the therapy’s safety, durability, and comparative performance across broader patient populations.

References

1. Fricke TR, Tahhan N, Resnikoff S, et al. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia. Ophthalmology. 2018;125(10):1492-1499. doi:10.1016/j.ophtha.2018.04.013. Available at: https://www.sciencedirect.com/science/article/pii/S0161642018307481

2. Holden BA, Fricke TR, Ho SM, et al. Global vision impairment due to uncorrected presbyopia. Arch Ophthalmol. 2008;126(12):1731-1739. doi:10.1001/archopht.126.12.1731. Available at: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/420393

3. United Nations, Department of Economic and Social Affairs. World population ageing reports. Available at: https://www.un.org/development/desa/pd/

4. Abdelkader A. Improved presbyopic vision with miotics. Eye Contact Lens. 2015;41(5):323-327. doi:10.1097/ICL.0000000000000123. Available at: https://journals.lww.com/claojournal/Fulltext/2015/09000/Improved_Presbyopic_Vision_with_Miotics.10.aspx

5. US Food and Drug Administration. FDA approves Vuity (pilocarpine HCl ophthalmic solution) for presbyopia. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-vuity-pilocarpine-hcl-ophthalmic-solution-presbyopia

6. Katz LJ, et al. Brimonidine tartrate: a review of its pharmacology and clinical use in glaucoma. Surv Ophthalmol. 1999;44(Suppl 1):S55-S67. Available at: https://www.sciencedirect.com/science/article/pii/S0039625799000506

7. Toker E, et al. Carbachol in ophthalmology: pharmacologic profile and clinical applications. Expert Opin Drug Metab Toxicol. 2010;6(3):383-391. doi:10.1517/17425250903571631. Available at: https://www.tandfonline.com/doi/full/10.1517/17425250903571631

8. ClinicalTrials.gov. Studies evaluating pharmacologic treatments for presbyopia. Available at: https://clinicaltrials.gov/